KUZELOVA, Katerina, Barbora BRODSKA, Johannes SCHETELIG, Christoph ROLLING, Zdeněk RÁČIL, Juliane Stickel WALZ, Grzegorz HELBIG, Ota FUCHS, Milena VRANA, Pavla PECHERKOVA, Cyril SALEK and Jiří MAYER. Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin. Plos one. San Francisco: Public Library of Science, 2018, vol. 13, No 12, p. 1-12. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0204290.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin
Authors KUZELOVA, Katerina (203 Czech Republic, guarantor), Barbora BRODSKA (203 Czech Republic), Johannes SCHETELIG (276 Germany), Christoph ROLLING (276 Germany), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Juliane Stickel WALZ (276 Germany), Grzegorz HELBIG (616 Poland), Ota FUCHS (203 Czech Republic), Milena VRANA (203 Czech Republic), Pavla PECHERKOVA (203 Czech Republic), Cyril SALEK (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition Plos one, San Francisco, Public Library of Science, 2018, 1932-6203.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.776
RIV identification code RIV/00216224:14110/18:00106958
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1371/journal.pone.0204290
UT WoS 000453451000008
Keywords in English Acute myeloid leukemia
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 9/2/2019 20:46.
Abstract
Acute myeloid leukemia with mutated nucleophosmin (NPMc+AML) forms a distinct AML subgroup with better prognosis which can potentially be associated with immune response against the mutated nucleophosmin (NPM). As the T-cell-mediated immunity involves antigen presentation on HLA class I molecules, we hypothesized that individuals with suitable HLA type could be less prone to develop NPMc+AML. We compared HLA class I distribution in NPMc+AML patient cohort (398 patients from 5 centers) with the HLA allele frequencies of the healthy population and found HLA-A*02, B*07, B*40 and C*07 underrepresented in the NPMc+AML group. Presence of B*07 or C*07:01 antigen was associated with better survival in patients without concomitant FLT3 internal tandem duplication. Candidate NPM-derived immunopeptides were found for B*40 and B*07 using prediction software tools. Our findings suggest that a T-cell-mediated immune response could actually explain better prognosis of NPMc+ patients and provide a rationale for attempts to explore the importance of immunosuppressive mechanisms in this AML subgroup.
Links
NV15-25809A, research and development projectName: Národní program studia mutací a klonality leukemických buněk u pacientů s akutní myeloidní leukémií
PrintDisplayed: 10/7/2024 06:15